British journal of cancer · 2016
BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hugdahl Emilia, Kalvenes May Britt, Puntervoll Hanne E, Ladstein Rita G, Akslen Lars A
Аннотация
BACKGROUND: Around 50% of primary melanomas harbour BRAF mutations, but their prognostic impact has not been clear. Recently, a BRAF-V600E mutation-specific antibody has become available for immunohistochemistry. Here, we investigated for the first time the prognostic impact of BRAF-V600E protein expression in primary melanoma.
METHODS: In a patient series of 248 nodular melanomas, BRAF-V600E and total BRAF expression were assessed by immunohistochemistry using tissue microarray sections of paraffin-embedded archival tissue. Mutation status was assessed by real-time PCR in cases with sufficient tumour tissue (n=191).
RESULTS: Positive BRAF-V600E expression was present in 86 (35%) of the cases, and was significantly associated with increased tumour thickness, presence of tumour ulceration and reduced survival. Further, BRAF-V600E expression was an independent prognostic factor by multivariate analysis, whereas BRAF mutation status was not significant. There was 88% concordance between BRAF-V600E expression and mutation status.
CONCLUSIONS: Our findings indicate that BRAF-V600E expression is a novel prognostic marker in primary melanoma.
METHODS: In a patient series of 248 nodular melanomas, BRAF-V600E and total BRAF expression were assessed by immunohistochemistry using tissue microarray sections of paraffin-embedded archival tissue. Mutation status was assessed by real-time PCR in cases with sufficient tumour tissue (n=191).
RESULTS: Positive BRAF-V600E expression was present in 86 (35%) of the cases, and was significantly associated with increased tumour thickness, presence of tumour ulceration and reduced survival. Further, BRAF-V600E expression was an independent prognostic factor by multivariate analysis, whereas BRAF mutation status was not significant. There was 88% concordance between BRAF-V600E expression and mutation status.
CONCLUSIONS: Our findings indicate that BRAF-V600E expression is a novel prognostic marker in primary melanoma.
Предметные рубрики MeSH
AdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMelanomaMiddle AgedMutationNeoplasm StagingPrognosisProto-Oncogene Proteins B-rafReal-Time Polymerase Chain ReactionSkin NeoplasmsSurvival RateTissue Array AnalysisYoung AdultCutaneous Malignant Melanoma